LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 178

Search options

  1. Article ; Online: Avoiding Checkmate-Playing Chess With Cancer.

    Desai, Aakash

    JAMA oncology

    2022  Volume 8, Issue 12, Page(s) 1740

    MeSH term(s) Humans ; Neoplasms
    Language English
    Publishing date 2022-09-23
    Publishing country United States
    Document type Journal Article
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2022.4422
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Response to Lin and Wei.

    Barnes, Edward L / Desai, Aakash / Kochhar, Gursimran S

    The American journal of gastroenterology

    2024  

    Language English
    Publishing date 2024-03-27
    Publishing country United States
    Document type Journal Article
    ZDB-ID 390122-1
    ISSN 1572-0241 ; 0002-9270
    ISSN (online) 1572-0241
    ISSN 0002-9270
    DOI 10.14309/ajg.0000000000002740
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Clinical Trials for Patients With Cancer.

    Abu Rous, Fawzi / Desai, Aakash / Singhi, Eric K

    JAMA oncology

    2024  Volume 10, Issue 3, Page(s) 416

    MeSH term(s) Humans ; Neoplasms/drug therapy ; Medical Oncology ; Patients ; Patient Selection
    Language English
    Publishing date 2024-01-25
    Publishing country United States
    Document type Journal Article
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2023.5778
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Hear Me Out: Mitigating Cisplatin-Induced Ototoxicity.

    Desai, Aakash / Das, Devika

    JCO oncology practice

    2023  Volume 19, Issue 5, Page(s) 284–285

    MeSH term(s) Humans ; Cisplatin/adverse effects ; Ototoxicity/etiology ; Antineoplastic Agents/adverse effects
    Chemical Substances Cisplatin (Q20Q21Q62J) ; Antineoplastic Agents
    Language English
    Publishing date 2023-03-29
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 3028198-2
    ISSN 2688-1535 ; 2688-1527
    ISSN (online) 2688-1535
    ISSN 2688-1527
    DOI 10.1200/OP.23.00120
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Challenges in the implementation of ultrasensitive liquid biopsy approaches in precision oncology.

    Desai, Aakash / Lovly, Christine M

    Journal for immunotherapy of cancer

    2023  Volume 11, Issue 6

    MeSH term(s) Humans ; Neoplasms/diagnosis ; Neoplasms/pathology ; Precision Medicine ; Liquid Biopsy ; Medical Oncology
    Language English
    Publishing date 2023-06-22
    Publishing country England
    Document type Letter ; Research Support, N.I.H., Extramural ; Comment
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2023-006793
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Toxicity From Sotorasib After Immune Checkpoint Inhibitors: A Note of Caution and Reflections of Future Advancements in the Field.

    Desai, Aakash / Dimou, Anastasios

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

    2023  Volume 18, Issue 10, Page(s) 1265–1267

    Language English
    Publishing date 2023-09-28
    Publishing country United States
    Document type Editorial
    ZDB-ID 2432037-7
    ISSN 1556-1380 ; 1556-0864
    ISSN (online) 1556-1380
    ISSN 1556-0864
    DOI 10.1016/j.jtho.2023.07.013
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Direct-to-Patient Clinical Trials: One Small Step or a Giant Leap?

    Desai, Aakash / Subbiah, Vivek

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2023  Volume 29, Issue 13, Page(s) 2339–2341

    Abstract: Genome driven precision oncology has transformed the landscape of multiple cancers. However, access barriers exist. A recent study exemplified a direct-to-patient outreach program via social media through the implementation of a global program that ... ...

    Abstract Genome driven precision oncology has transformed the landscape of multiple cancers. However, access barriers exist. A recent study exemplified a direct-to-patient outreach program via social media through the implementation of a global program that offered free tumor genomic testing with a focus on rare cancers. See related article by Doe-Tetteh et al., p. 2445.
    MeSH term(s) Humans ; Neoplasms/drug therapy ; Neoplasms/genetics ; Precision Medicine ; Genomics ; Medical Oncology
    Language English
    Publishing date 2023-01-28
    Publishing country United States
    Document type Editorial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-23-0746
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Immunotherapy-based combinations in metastatic NSCLC.

    Desai, Aakash / Peters, Solange

    Cancer treatment reviews

    2023  Volume 116, Page(s) 102545

    Abstract: Immuno-oncology has revolutionized the treatment of metastatic non-small cell lung cancer (mNSCLC) since the approval of immunotherapy by the U.S. FDA in 2015. Despite the advancements, outcomes for patients have room for further improvement. Combination ...

    Abstract Immuno-oncology has revolutionized the treatment of metastatic non-small cell lung cancer (mNSCLC) since the approval of immunotherapy by the U.S. FDA in 2015. Despite the advancements, outcomes for patients have room for further improvement. Combination therapies have shown promise in overcoming resistance and improving outcomes. This review focuses on current immunotherapy-based combination approaches, reported and ongoing trials, as well as novel combination strategies, challenges, and future directions for mNSCLC treatment. We summarize approaches in combination with chemotherapy, novel immune checkpoints, tyrosine kinase inhibitors and other strategies including vaccines, and radiation therapy. The promise of biomarker-driven studies to understand resistance and design multi-arm platform trials that evaluate novel therapies is becoming of increasing relevance with the ultimate goal of administering precision immunotherapy by identifying the right dose of the right combination for the right patient at the right time.
    MeSH term(s) Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/pathology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Immunotherapy ; Combined Modality Therapy
    Language English
    Publishing date 2023-03-27
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 125102-8
    ISSN 1532-1967 ; 0305-7372
    ISSN (online) 1532-1967
    ISSN 0305-7372
    DOI 10.1016/j.ctrv.2023.102545
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review.

    Desai, Aakash / Lovly, Christine M

    Translational lung cancer research

    2023  Volume 12, Issue 3, Page(s) 615–628

    Abstract: Background and objective: Anaplastic lymphoma kinase (ALK) rearrangements are detected in 3-7% of advanced non-small cell lung cancer (NSCLC). There are currently 5 U.S Food and Drug Administration (FDA)-approved ALK tyrosine kinase inhibitors (TKIs) ... ...

    Abstract Background and objective: Anaplastic lymphoma kinase (ALK) rearrangements are detected in 3-7% of advanced non-small cell lung cancer (NSCLC). There are currently 5 U.S Food and Drug Administration (FDA)-approved ALK tyrosine kinase inhibitors (TKIs) for the treatment of patients with ALK-positive lung cancer in the advanced/metastatic disease setting. Despite these advances, most patients with ALK-positive lung cancer who are treated with ALK TKI therapy ultimately experience disease progression due to various mechanisms of drug resistance. In this review, we discuss strategies to address acquired therapeutic resistance to ALK inhibition, novel agents and combinatorial strategies in development for both on and off-target resistance, and some emerging approaches to prolong response to ALK inhibitors.
    Methods: We performed a search of peer-reviewed literature in the English language, conference abstracts, and trial registrations from the MEDLINE (Ovid), Embase (Elsevier), and CENTRAL (Cochrane Library) databases and major international oncology meetings up to August 2022. We then screened for studies describing interventions to overcome ALK resistance based on review of each title and abstract.
    Key content and findings: For patients with oligo-progression, treatment may include maintaining the same systemic treatment beyond progression while adding local therapies to progressing lesions. Strategies to combat ALK TKI resistance mediated by on-target resistance mechanisms include 4
    Conclusions: Strategies to overcome resistance to currently available ALK inhibitors are urgently needed. Given the variety of resistance mechanisms, tailormade approaches are required for disease control.
    Language English
    Publishing date 2023-03-20
    Publishing country China
    Document type Journal Article ; Review
    ZDB-ID 2754335-3
    ISSN 2226-4477 ; 2218-6751
    ISSN (online) 2226-4477
    ISSN 2218-6751
    DOI 10.21037/tlcr-22-708
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Rationalizing rules for immunotherapy combination trials: About time for precision immunotherapy.

    Desai, Aakash / Subbiah, Vivek

    Cancer

    2022  Volume 129, Issue 1, Page(s) 11–14

    Abstract: Immunotherapy has changed the landscape of cancer treatment. However, the benefit of immunotherapy is seen only in some cases, with most patients experiencing cancer progression despite treatment with immunotherapy. To overcome this, combination ... ...

    Abstract Immunotherapy has changed the landscape of cancer treatment. However, the benefit of immunotherapy is seen only in some cases, with most patients experiencing cancer progression despite treatment with immunotherapy. To overcome this, combination immunotherapy treatments are being studied. Herein, we propose for a precision-driven approach for patient selection to identify successful combinations of immunotherapy to improve outcomes for patients with cancer.
    MeSH term(s) Humans ; Immunotherapy ; Neoplasms/therapy
    Language English
    Publishing date 2022-10-30
    Publishing country United States
    Document type Editorial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1429-1
    ISSN 1097-0142 ; 0008-543X ; 1934-662X
    ISSN (online) 1097-0142
    ISSN 0008-543X ; 1934-662X
    DOI 10.1002/cncr.34514
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top